Michael Potter

Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Lucy Pickard, Li Yuan Chan, Su Li, Michael Potter et autres

Primary mediastinal B-cell lymphoma (PMBL) is a rare but aggressive subtype of non-Hodgkin lymphoma that predominantly occurs in adolescents and young adults. Most patients (>95%) are cured after first line treatment and those with relapsed refractory (R/R) disease have poor outcomes, with …

gb (code pays fourni par la source)

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC)

Alan Wigg, Jonathan Tibballs, Richard Woodman, Katherine Stuart et autres

BACKGROUND: Therapeutic options for early-stage hepatocellular carcinoma (HCC) in individual patients can be limited by tumor and location, liver dysfunction and comorbidities. Many patients with early-stage HCC do not receive curative-intent therapies. Stereotactic ablative body radiotherapy (SABR) has emerged as an effective, …

au, gb (code pays fourni par la source)

Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Farheen Mir, Anna Robinson, Mark Ethell, Michael Potter et autres

gb (code pays fourni par la source)

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

David I. Marks, Laura Clifton‐Hadley, Mhairi Copland, Jiaull Hussain et autres

gb (code pays fourni par la source)

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Cost Evaluation Study of Management and Surveillance, and Review of the Recent USA and UK Guidelines

Aia Mehdi, Rachel O’Connell, Michael Potter, Chris Marshall et autres

Abstract Introduction Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a T-cell lymphoma associated with textured breast implants, recently recognized by the revised WHO Classification. Recommended management for BIA-ALCL involves a multidisciplinary team (MDT) approach with breast surgery, haemato-oncology, pathology, radiology and …

gb (code pays fourni par la source)

178: Long-term impact of ivacaftor on health outcomes and mortality in people with cystic fibrosis in the U.S. CF Foundation Patient Registry (CFFPR)

Christian A. Merlo, Maral DerSarkissian, Christen Nguyen, Yitao Gu et autres

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Patrick Hayden, Dirk-Jan Eikema, Liesbeth C. de Wreede, Linda Köster et autres

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) …

ie, nl, de, it, gb, ch, es, fr, se, tr (code pays fourni par la source)

Impact of detectable measurable residual disease on umbilical cord blood transplantation

Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, Jorge Sierra et autres

The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. Inclusion criteria included …

be, fr, mc, it, es, gb, us, il (code pays fourni par la source)

Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML

Will P. Bultitude, Jennifer Schellekens, Richard Szydlo, Chloe Anthias et autres

gb, us, mx (code pays fourni par la source)

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Matt Cross, Monica Else, Ricardo Morilla, Mark Ethell et autres

BACKGROUND: T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive, post thymic lymphoid malignancy, with an incidence of approximately 0.1/100,000 people. T-PLL accounts for ~2% of all mature lymphocytic leukaemias in adults >30 years. Median overall survival (OS) ~20 months and long term …

gb (code pays fourni par la source)

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Patrick Hayden, Dirk‐Jan Eikema, Linda Köster, Hartmut Goldschmidt et autres

Introduction The use of autologous haematopoietic cell transplantation (auto-HCT) in the treatment of myeloma (MM) has greatly increased over the last twenty-five years. There are, however, few large datasets detailing the overall trends in transplant use, patient selection, induction regimen, choice of …

ie, nl, de, fr, gb, se, hu, cz, gr, it, tr (code pays fourni par la source)

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Stefan Schönland, Simona Iacobelli, Linda Köster, Didier Blaise et autres

Introduction Although many new drugs became available to treat multiple myeloma (MM), high-dose chemotherapy with auto-HCT remains the gold standard. Further intensification to improve disease control has been assessed in several trials. However, no clear consensus has emerged. Further evidence is therefore …

de, it, nl, fr, gb, cz, hu, no, tr, ie (code pays fourni par la source)